Trulieve CEO Sells $1.2 Million in Stock as Shares Jump 148% in Year

Kim Rivers, chairman and CEO of Trulieve Cannabis Corp. (NYSE:TRLV), sold 136,811 shares for roughly $1.2 million on June 26, according to an SEC filing. The transaction came as the stock trades near the top of a yearlong rally that has pushed the share price up 148%.

Rivers held more than 1.5 million shares after the sale, the filing shows. The transaction was not executed under a Rule 10b5-1 trading plan, which would have prearranged the sale in advance. Discretionary insider sales at multiyear highs draw attention from traders who track management's view of the stock.

Trulieve dominates Florida's medical cannabis market with more than 120 dispensaries across the state. Florida is the largest medical-only cannabis market nationwide, with over 700,000 registered patients. Single-state exposure leaves the company vulnerable to policy or competitive shifts in that state. A recreational marijuana ballot measure set for November has generated optimism. Its outcome remains uncertain. Trulieve's vertical integration – it controls cultivation, processing, and retail – gives it a cost advantage over peers that rely on wholesale supply.

Federal prohibition on cannabis limits access to traditional banking and capital markets. The SAFE Banking Act has passed the House multiple times. It has never cleared the Senate. Until that changes, cannabis operators rely on cash and alternative financing, which raises borrowing costs and limits expansion options. Trulieve's ability to fund growth without selling equity is a key metric for the stock's premium valuation.

The stock trades at roughly 28 times trailing earnings, a premium to most peers like Curaleaf and Green Thumb. Recent quarterly results showed revenue climbing. Operating costs rose faster, squeezing gross margins. The company has been investing in cultivation capacity outside Florida, a capital spending plan that will take time to generate returns. Trulieve has not reported a full-year GAAP profit.

Cannabis stocks are known for sharp moves in both directions. Doubling in months and then giving back half the gain is common within the sector. Rivers' sale removes a visible vote of confidence from the top of the organization at a valuation that leaves little room for execution errors.

Without a prearranged trading plan, the timing of the sale carries more weight. The CEO has not publicly commented on the transaction. The filing did not specify a reason for the sale. The $1.2 million sale is small relative to Rivers' total stake. The discretionary nature means it was a direct decision.

Insider sales by top executives are not always signals of near-term weakness. Rivers retains a large stake, and the sale could reflect personal financial planning. The absence of a 10b5-1 plan, however, makes it harder for the market to dismiss the timing. For a stock that has already delivered a 148% return in twelve months, the risk of a pullback is elevated regardless of the CEO's motives.

Trulieve faces competition from new entrants in Florida's medical market. Dispensary license approvals have increased, putting pressure on market share. The company's strong brand and scale have so far defended its position.

The August earnings report will be the next major catalyst. Traders will focus on same-store sales growth and gross margin trends.

The stock's current multiple prices in continued growth in Florida and eventual federal reform. A delay in either case would pressure the stock.

Trulieve's next quarterly report is due in mid-August.